Company intelligence / Profile preview

Four 20 Pharma

Paderborn, Nordrhein-Westfalen, Germany420pharma.de ↗

Ownership: Private
Development stage: Other

Overview

Four 20 Pharma is a leading German manufacturer, importer, and wholesaler of medicinal cannabis flowers and full-spectrum extracts. The company operates under GMP certification, ensuring high quality and consistency in its products. It has established itself as one of the largest players in the German medical cannabis market since its founding in 2018. In August 2022, Curaleaf acquired a majority stake for $20.4 million. The company is also notable for exclusive partnerships to bring elite genetics to European patients.

Therapeutic areas: NeurologyOncology
Modalities: Plant-derived therapy (medical cannabis)
Industry: Biotech

Partnerships

Compound Genetics – exclusive partnership to bring elite US-bred cultivars to Germany/Europe

Beyond the preview

Go deeper on Four 20 Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Four 20 Pharma.

Explore the full profile